Development of anticancer drugs based on the hallmarks of tumor cells

被引:28
作者
Bailon-Moscoso, Natalia [1 ,2 ]
Carlos Romero-Benavides, Juan [3 ]
Ostrosky-Wegman, Patricia [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Dept Med Genom & Toxicol Ambiental, Inst Invest Biomed, Mexico City 04510, DF, Mexico
[2] UTPL, Dept Ciencias Salud, Loja, Ecuador
[3] UTPL, Dept Quim, Loja, Ecuador
关键词
Cancer cell hallmarks; Drug design; Cancer; NF-KAPPA-B; APOPTOSIS-BASED THERAPIES; PARP INHIBITORS; POLY(ADP-RIBOSE) POLYMERASE; TELOMERASE INHIBITOR; THERAPEUTIC TARGETS; SIGNAL-TRANSDUCTION; GENOMIC INSTABILITY; ANTITUMOR-ACTIVITY; CANCER PREVENTION;
D O I
10.1007/s13277-014-1649-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer remains a public health problem with a high unmet medical demand. However, in recent decades, the knowledge of several functional molecular and biological traits that distinguish tumor cells from normal cells, known as the hallmarks of cancer as described by Hannahan and Weinberg, has led to new and modern therapeutic approaches against this disease. Most cancer drugs are deliberately developed for specific molecular targets that involve these hallmarks. In this review, we address the currently available cancer drugs and development of new drugs from the perspective of their interaction with these hallmarks as well as the pathways and mechanisms involved.
引用
收藏
页码:3981 / 3995
页数:15
相关论文
共 184 条
[1]   Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].
Advani, Ranjana ;
Forero-Torres, Andres ;
Furman, Richard R. ;
Rosenblatt, Joseph D. ;
Younes, Anas ;
Ren, Hong ;
Harrop, Kate ;
Whiting, Nancy ;
Drachman, Jonathan G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377
[2]   Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death [J].
Aft, RL ;
Zhang, FW ;
Gius, D .
BRITISH JOURNAL OF CANCER, 2002, 87 (07) :805-812
[3]   Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe [J].
Aggarwal, Bharat B. ;
Vijayalekshmi, R. V. ;
Sung, Bokyung .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :425-430
[4]   Opinion - Survivin, cancer networks and pathway-directed drug discovery [J].
Altieri, Dario C. .
NATURE REVIEWS CANCER, 2008, 8 (01) :61-70
[5]   Targeting survivin in cancer [J].
Altieri, Dario C. .
CANCER LETTERS, 2013, 332 (02) :225-228
[6]  
Annunziata C, 2011, CLIN CANCER RES, V16, P4517
[7]   Survivin Is a Therapeutic Target in Merkel Cell Carcinoma [J].
Arora, Reety ;
Shuda, Masahiro ;
Guastafierro, Anna ;
Feng, Huichen ;
Toptan, Tuna ;
Tolstov, Yanis ;
Normolle, Daniel ;
Vollmer, Laura L. ;
Vogt, Andreas ;
Doemling, Alexander ;
Brodsky, Jeffrey L. ;
Chang, Yuan ;
Moore, Patrick S. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (133)
[8]   Antivascular therapy of cancer: DMXAA [J].
Baguley, BC .
LANCET ONCOLOGY, 2003, 4 (03) :141-148
[9]   Cancer and Inflammation: Implications for Pharmacology and Therapeutics [J].
Balkwill, F. ;
Mantovani, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (04) :401-406
[10]   Tumour necrosis factor and cancer [J].
Balkwill, Frances .
NATURE REVIEWS CANCER, 2009, 9 (05) :361-371